Credit Suisse
First quarter revenue was below Credit Suisse forecasts. US mask sales were flat and management notes some loss of share as well as distributors potentially holding back purchases ahead of the launch of new products.
New mask products are needed to drive growth and the broker believes this, in turn, should lead to a recovery in gross margin.
Target is reduced to $9.00 from $9.40 and Outperform retained.
Sector: Health Care Equipment & Services.
Target price is $9.00.Current Price is $8.08. Difference: $0.92 - (brackets indicate current price is over target). If RMD meets the Credit Suisse target it will return approximately 10% (excluding dividends, fees and charges - negative figures indicate an expected loss)
ResMed's profit down despite revenue rise, page-11
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.39 |
Change
0.390(1.05%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.30 | $37.39 | $37.07 | $9.449M | 253.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $37.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.39 | 2573 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
